Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program
Bitget2026/09/23 12:02- Lexeo Therapeutics entered an agreement with Apertura Gene Therapy for access to TfR1 CapX for a Friedreich ataxia gene-therapy program.
- TfR1 CapX is an intravenously delivered AAV capsid designed to target hTfR1 and cross the blood-brain barrier.
- Lexeo plans to evaluate a less invasive CNS delivery route following initial systemic administration of LX2006.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
